Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immune Response Remune, Unimed NTZ cleared for expanded access by FDA.

Executive Summary

IMMUNE RESPONSE REMUNE EXPANDED ACCESS PROGRAM TO ADD 2,000 PATIENTS with CD4 cell counts under 300 or above 550, the company said Oct. 15. FDA authorized expanded access for the gp120-depleted inactivated "Salk" HIV-1 immunogen to individuals who cannot participate in the Phase III trial, which was limited to patients with CD4 cell counts between 300 and 550.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS029032

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel